| 10492ETCTN |
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced
Head and Neck Cancer |
Open |
| 10629ETCTN |
A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with
Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients
with Extensive-Stage Small Cell Lung Cancer |
Open |
| 10637ETCTN |
Phase 2 Study of Venetoclax in Relapsed Classic or Variant Hairy Cell Leukemia |
Open |
| 10674ETCTN |
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination
with ASTX727 in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia
(AML) |
Open |
| 1403GCC |
An Umbrella Protocol for Collection of Blood, Tumor Tissue, Lymph Node Specimens,
normal tissue, effusions CSF fluid and Buccal Samples from Patients with Established
or Suspected Solid Tumor Malignancy and Normal Subjects, to be used in Laboratory
Research |
Open |
| 1495GCC |
An Umbrella Protocol for the Collection of Blood and Biological Samples from Patients
with Established or Suspected Thoracic Malignancies and Normal Subjects, to Be Used
in Laboratory Research |
Open |
| 1563GCC |
Mitigation of radiation pneumonitis and fibrosis |
Open (affiliates only) |
| 16115GCC |
Integration of Cancer Health Activities into African American Churches |
Open (affiliates only) |
| 1697684-1 |
1697684-1: Project HEAL Community Health Advisor (CHA) Training |
Open |
| 1718GCCC-S17 |
A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, azacitidine (Aza) and
venetoclax (Ven) in newly diagnosed, untreated Acute Myeloid Leukemia (AML) Patients
>/= 60 years with NPM1 mutated AML or Mixed Lineage Leukemia (MLL) Gene Rearrangements |
Open |
| 1718GCCC-S24 |
Phase 1b safety run-in study followed by Phase 2 study of Ficlatuzumab, Azacitidine
and Venetoclax in Untreated Acute Myeloid Leukemia (AML) patients aged >/= 60 years
old |
Open |
| 1775GCCC |
DNA methylation at chromosome 8q24 and the risk of aggressive prostate cance |
Open |
| 1886GCC |
Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine with Hypofractionated, Ablative
Proton Therapy for Locally Advanced Pancreatic Cancer |
Open |
| 19108GCCC |
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability,
Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid
Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) |
Open |
| 19140GCCC |
PILOT STUDY OF LASER INTERSTITIAL THERMAL THERAPY FOLLOWED BY HYPOFRACTIONATED RADIATION
THERAPY FOR RECURRENT HIGH GRADE GLIOMAS |
Open |
| 1926GCCC |
A Phase I Dose Escalation Study of Single Fraction Pre-operative Partial Breast S-PBI
for Early Stage Breast Cancer |
Open |
| 1946GCCC |
A Phase II Study of Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor
with Fractionated Gemtuzumab Ozogamicin (CLAG-GO) for the Treatment of Patients with
Persistent, Relapsed or Refractory Acute Myeloid Leukemia |
Open |
| 1949GCCC |
GP-88 Levels in Metastatic Breast Cancer: A Prospective Blood Sampling trial |
Open |
| 1950GCCC |
First in Human Phase 1A (dose escalation) and I B (expansion cohorts) Study of [IND
# Agent-AG01 a Chimeric Monoclonal Antibody against Glycoprotein GP88] in advanced
Solid Tumor Malignancies (1A) with expansion cohorts (1B) in advanced Triple Negative
Breast Cancer, Hormone Resistant Breast Cancer, advanced Non-small Cell Lung Cancer
(NSCLCA) and advanced Mesothelioma |
Open |
| 1971456-1 |
1971456-1: UMGCCC Community Research Forums |
Open |
| 1973296-9 |
1973296-9: Multi-level drivers of cancer disparities impacting African Americans |
Open |
| 1985GCCC |
Managed Access Program (MAP) Cohort Treatment Plan CCTL019B20031 to provide access
for patients with out of specification leukapheresis product and/or out of specification
manufactured tisagenlecleucel (CTL019; Kymriah) |
Open |
| 20138GCC |
LASER INTERSTITIAL THERMAL THERAPY FOLLOWED BY HYPOFRACTIONATED RADIATION THERAPY
FOR TREATMENT OF NEWLY DIAGNOSED HIGH-GRADE GLIOMAS |
Open |
| 20139GCCC |
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145)
in Patients with Metastatic Non-Small-Cell Lung Cancer (IOV-LUN-202) |
Open |
| 2031GCCC |
Polyploid giant cancer cells actuate prostate cancer tumor resistance and lethal phenotype |
Open |
| 2032GCC |
Feasibility of Strength Training with Androgen Deprivation and Proton Therapy for
High Risk Prostate Cancer |
Open |
| 2048GCC |
A PHASE I DOSE ESCALATION STUDY OF HYPOFRACTIONATED ACCELERATED PELVIC NODAL RADIOTHERAPY
DELIVERED WITH A SIMULTANEOUSLY INTEGRATED PROSTATE BOOST FOR PATIENTS WITH LOCALIZED,
INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER
|
Open |
| 2050GCCC |
A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically
engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen
receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
(M-2018-344) |
Open |
| 2078GCCC |
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum
(R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large
B-Cell Lymphoma (RR DLBCL) |
Open |
| 2080GCCC |
Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that
is Nonconforming for Commercial Release |
Open |
| 2092GCCC |
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363
or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed
and/or Refractory B-cell Lymphoma |
Open |
| 2095GCCC |
A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients
with Relapsed or Refractory Acute Myeloid Leukemia |
Open |
| 21113GCCC |
Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing
Loss among Individuals with Head and Neck Cancer |
Open |
| 21133GCCC |
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab
Vedotin (MK-2140) in Combination with Standard of Care in Participants with Relapsed
or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) |
Open |
| 21136GCC |
Phase 2 randomized Total Eradication of metastatic lesions following definitive Radiation
to the Prostate in de novo oligometaStatic prostate cancer (TERPS) trial
|
Open |
| 21137GCCC |
The effects of exercise and nutrition interventions on chemotherapy-induced peripheral
neuropathy and interoceptive brain circuitry |
Open (affiliates only) |
| 2128GCCC |
Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That
Is Nonconforming for Commercial Release |
Open |
| 2136GCCC |
A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered
HQP1351 in Subjects with Refractory Chronic Myeloid Leukemia (CML) And Acute Lymphoblastic
Leukemia (ALL) |
Open |
| 2180GCCC |
Outcomes in acute myeloid leukemia treated with gemtuzumab ozogamicin versus anthracycline-based
regimens: A multi-institutional review |
Open |
| 22105GCCC |
22105GCCC:Nurse management of older cancer patient symptoms (HP-00101033) |
Open |
| 22115GCCC |
The safety and efficacy of cyclin-dependent kinases 4/6 inhibitors in older adults
with breast cancer |
Open |
| 22117GCCC |
22117GCCC:AYA Adaptation in serious pediatric illness (HP-00103465) |
Open |
| 22118GCCC |
22118GCCC:Colon cancer tissue and molecular analysis (HP-00098587) |
Open |
| 22121GCCC |
A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting
Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor
and Moderate Liver Impairment |
Open |
| 22125GCCC |
22125GCCC:Outcomes of Patients with Invasive Breast Cancer (Hormone Positive, HER-2
Positive, Triple Negative) in an Urban, Single Center Institution (HP-00102963) |
Open |
| 22128GCCC |
Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE) |
Open |
| 2212GCCC |
GCC 2212- Protons for Rectal Cancer after Prior Prostate Cancer |
Open (affiliates only) |
| 22130GCCC |
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy
and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line
Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23) |
Open |
| 22132GCCC |
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic
Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma |
Open |
| 2221GCCC |
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics,
and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced
MTAP-null Solid Tumors |
Open |
| 2228GCCC |
Effects of exercise during platinum chemotherapy on neuropathy: examining the interoceptive
brain system and inflammation (HP-00100000) |
Open (affiliates only) |
| 2230GCCC |
BT012:A randomized pivotal study assessing the efficacy of targeted blood-brain barrier
(BBB) disruption using Exablate focused ultrasound during the standard of care treatment
of brain metastases of non-small cell lung cancer (NSCLC) origin |
Open |
| 2242GCCC |
Hybrid Virtual MRI/CBCT for Image Guidance in Liver Radiation Therapy |
Open (affiliates only) |
| 2246GCCC |
2246GCCC:Prognostic factors, treatment patterns and outcomes for multiple myeloma
(HP-00100621) |
Open |
| 2247GCCC |
2247GCCC: Immunologic Biomarkers and Survival Outcomes in Primary Liver Cancers that
Underwent Locoregional Treatment (HP-00100844) |
Open |
| 2250GCCC |
A Pivotal Study to Evaluate the Safety and Effectiveness of Exablate
Model 4000 using Microbubble Resonators to Temporarily Mediate
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects
with Glioblastoma Brain Tumors (BT015) |
Open |
| 2252GCCC |
2252GCCC:Predictors of time to relapse after transplant in multiple myeloma ( HP-00101322) |
Open |
| 2254GCCC |
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific
DART Molecule, in Patients with Select Relapsed or Refractory Hematologic Malignancies |
Open |
| 2255GCCC |
A phase II trial of durvalumab (MEDI4736) and tremelimumab in combination with chemotherapy
in HIV-infected patients with non-small-cell lung cancer |
Open |
| 2267GCCC |
2267GCCC:Integrated Model for the Prevention of Anal Cancer using screen and Treat
for HSIL (IMPACT) (HP-00101383) |
Open |
| 2276GCCC |
2276GCCC:comparison of core cell blocks obtained via different modalities (HP-00101323) |
Open (affiliates only) |
| 2280GCCC |
Leveraging Technology to Address POST-Treatment Health Outcomes of Cancer Survivors
(POSTHOC-II): A Phase II Survivorship Care Plan Randomized Controlled Trial (HP-00100473) |
Open (affiliates only) |
| 2282GCCC |
A prospective randomized, double-blind, placebo-controlled, multi-center phase III
study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance
treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic
cell transplantation (HCT) |
Open |
| 2290GCCC |
A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study
to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory
(r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) |
Open |
| 23100GCC |
A randomized trial of high-risk Metachronous Oligometastatic prostate cancer with
High-risk mutations treated with metastasis directed therapy and Niraparib/Abiraterone
Acetate and Prednisone (KNIGHTS) |
Open |
| 23103GCCC |
A phase 3 randomized, open-label study of OP-1250 monotherapy vs standard of care
for the treatment of ER+, HER2- advanced or metastatic breast cancer following endocrine
and CDK 4/6 inhibitor therapy (OPERA-01) |
Open |
| 23106GCCC |
23106GCCC:A National Translational Science Network of Precision-based Immunotherapy
for Primary Liver Cancer (PLC) (HP-00108168) |
Open |
| 23117GCCC |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Ficlatuzumab
In Combination With Cetuximab In Participants With Recurrent Or Metastatic (R/M) Hpv-Negative
Head And Neck Squamous Cell Carcinoma (FIERCE-HN) |
Open |
| 23118GCCC |
23118GCCC: Surrogacy for OS in Stage IIB/C Melanoma Using Real-World Data (HP- 00108622) |
Open |
| 23121GCCC |
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate
or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer
(mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based
Chemotherapy |
Open |
| 2320GCCC |
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification
Brexucabtagene Autoleucel |
Open |
| 2325GCCC |
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification
Axicabtagene Ciloleucel |
Open |
| 2326GCCC |
2326GCCC:Pilot Studies – Physiologic Estrogen Assay Reliability and Preliminary
Data(HP- 00105142) |
Open |
| 2327GCCC |
2327GCCC: HIV lymphoma/Analysis of clinical presentations, outcomes, and toxicities
in patients with HIV lymphoma treated at the University of Maryland (HP-00105229) |
Open |
| 2328GCCC |
2328GCCC:Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in
Early-Stage Hepatocellular Carcinoma: A Surrogacy Analysis on Real-World Data (HP-
00104129) |
Open |
| 2332GCCC |
A Multicenter Open label Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib
Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR
Mutations Only Including L861Q G719X and/or S768I) |
Open |
| 2350GCCC |
2350GCCC: A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic
Immunotherapy in Combination with Second-line Therapy in Patients with
Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular
Carcinoma |
Open |
| 2361GCCC |
Phase II trial to evaluate immune-related biomarkers for pathological response in
stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent
randomization to multi-epitope HER2 vaccine vs. placebo in patients with residual
disease post-neoadjuvant chemotherapy |
Open |
| 2372GCCC |
A Phase Ia open-label Study of Tri-specific autologous CD19.20.22 Chimeric Antigen
Receptor (CAR) T-cells for Patients with Relapsed/Refractory B-Cell Lymphomas |
Open |
| 2374GCCC |
2374GCCC:The Impact of the COVID-19 pandemic on Healthcare Utilization (HP-00104540) |
Open |
| 2379GCC |
IImplications of Religious Beliefs, Mistrust and Other Psychosocial, Demographic and
Economic Variables Influencing a Patient's Decision on Enrolling in Radiation-Specific
Cancer Trials |
Open |
| 2380GCC |
A Single Arm phase I-II trial Evaluating Selective Adjuvant Therapy for HPV-mediated
Oropharynx SCCs based on Residual Circulating Tumor DNA (ctDNA) Levels (SAVAL) |
Open |
| 2383GCCC |
ADRIAN: Towards understanding of ADT treatment and dietary patterns,
circadian rhythm, physiological responsiveness, and frailty (HP-00106546) |
Open (affiliates only) |
| 2387GCCC |
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for
Improved Survival and Treatment Effectiveness |
Open |
| 2393GCCC |
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study
comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay
castration or disease recurrence in adult male patients with prostate-specific membrane
antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) |
Open |
| 2402GCCC |
A Prospective, Observational, Long-term Follow-up Study for Subjects who Previously
Received Zamtocabtagene Autoleucel in a United States Miltenyi Biomedicine-Sponsored
Clinical Study |
Open |
| 2406GCCC |
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host
Disease in the United States (THRIVE) |
Open |
| 2408GCCC |
2408GCCC: Utilization of Active Surveillance (AS), and Direct Medical Costs in Medicare
Beneficiaries Diagnosed with Localized Prostate Cancer (HP-00108653) |
Open |
| 2409GCCC |
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy
of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in
Previously Untreated Follicular Lymphoma (EPCORE FL-2) |
Open |
| 24101GCCC |
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult
Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and
without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation |
Open |
| 24102GCCC |
Targeting CD38 in Lymphoma |
Open |
| 24103GCCC |
A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the
Treatment of Early-Stage Anal Cancer |
Open |
| 24105GCCC |
Registry and Biobank of Patients with a History of Cancer Therapy |
Open |
| 24106GCCC |
24106GCCC: Retrospective evaluation of proton and photon-based radiotherapy for treatment
of sarcoma |
Open |
| 24111GCCC |
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination
with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination
with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated
Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Open |
| 24112GCCC |
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone
versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as
Maintenance Therapy Following Autologous Stem Cell Transplantation |
Open |
| 24113GCCC |
A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors |
Open |
| 24114GCCC |
24114GCCC: My Healthy Maryland Precision Medicine Research |
Open |
| 24116GCCC |
24116GCCC: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune®
(TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus
Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of
Newly Diagnosed Glioblastoma |
Open |
| 24117GCC |
Setup for prone breast external beam radiation therapy: skin-based marker and/or VisionRT |
Open |
| 2411GCCC |
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition
to Other Therapeutic Agents in Participants with Head and Neck Squamous Cell Carcinoma
|
Open |
| 2412GCCC |
A Phase 2 Study of PLK1 inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer |
Open |
| 2415GCCC |
REMASTer: REcurrent brain Metastases After SRS Trial |
Open |
| 2419GCCC |
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with
an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer |
Open |
| 2421GCCC |
A phase 2 study of alisertib in patients with extensive stage small cell lung cancer
|
Open |
| 2422GCCC |
Phase I Feasibility and Pilot RCT of Serious Illness Conversation Guide in Patient
and Intimate Partner Dyads Living with Advanced Lung Cancer
|
Open |
| 2429GCCC |
A Phase 1b, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants
with Relapsed Refractory Multiple Myeloma |
Open |
| 2433GCCC |
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination
with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2-
Unresectable Locally Advanced or Metastatic Breast Cancer. |
Open |
| 2436GCCC |
2436GCCC:A feasibility study to improve dietary quality among older cancer survivors
with impaired mobility, Part 1 Photovoice (HP-00109419) |
Open |
| 2438GCCC |
2438GCCC:Reaching Every Diagnosed But Untreated Hepatitis B/C patient through Support
(HP-00109140) |
Open |
| 2440GCCC |
2440GCCC: Deficits in Cellular Redox Balance in Survivors of Lower Extremity Sarcoma:
A Potential Target for Improving Recovery Time, Function, and Quality of Life. |
Open |
| 2441GCCC |
Tempus GEMINI NSCLC Study: A Longitudinal Multi-Omic Biomarker Profiling Study of
Patients with Non-Small Cell Lung Cancer (NSCLC) |
Open |
| 2445GCCC |
2445GCCC: Implementation of an At-Home Multimodal Integrative Therapy Via Virtual
Reality for Patients with Cancer-Treatment Associated Symptoms |
Open |
| 2448GCCC |
2448GCCC: Retrospective Chart Review of incidental pulmonary nodules in the Emergency
Care Setting |
Open |
| 2449GCCC |
GCCC:2449 Signature Development and Validation Protocol for an Epigenetic Assay in
Diagnosing Lung Cancer |
Open |
| 2450GCCC |
2450GCCC: Characteristics, biomarkers, and outcome of patients with acute lymphoblastic
leukaemia at University of Maryland Medical Center: A Retrospective Cohort Study |
Open |
| 2451GCCC |
2451GCCC: Characteristics, clinical and genetic biomarkers, and outcomes of patients
with acute myeloid leukaemia at University of Maryland Medical Centre: A Retrospective
Cohort Study |
Open |
| 2452GCCC |
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study Of Olverembatinib
(HQP1351) In Patients With Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) |
Open |
| 2453GCCC |
2453GCCC: Oncology Patient Perspectives on Medical Cannabis Use |
Open |
| 2454GCCC |
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy
of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed
Chronic Graft-Versus-Host Disease |
Open |
| 2456GCCC-01A |
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol
to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684
Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) |
Open |
| 2458GCCC |
Take the Reins: The effects of nutrient timing on cancer-related fatigue among blood
cancer survivors |
Open |
| 2459GCCC |
2459GCCC: Evaluation of unusual responders to cancer treatments |
Open |
| 2467GCCC |
2467GCCC: HP-00110389: Creation of Virtual Digital Pathology Images with Artificial
Intelligence and Machine Learning - Based Algorithm |
Open |
| 2471GCCC |
A First-in-human Phase I, non-randomized, open-label, multicenter dose escalation
trial of BI 764532 administered by parenteral route in patients with Small Cell Lung
Carcinoma and other neuroendocrine neoplasms expressing DLL3 |
Open |
| 2472GCCC |
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous
BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage
small cell lung cancer and in patients with other relapsed/refractory neuroendocrine
carcinoma |
Open |
| 2473GCCC |
2473GCCC: CASCADE Network Cervical Cancer Screening and Precancer Treatment Clinical
Data Repository (Project CN001) |
Open |
| 2474GCCC |
2474GCCC: Assessing the risk of Hepatitis B virus reactivation in patients with solid
tumor or hematologic malignancies on immunotherapies |
Open |
| 2475GCCC |
A Retrospective Review of Patients Treated with CAR-T Therapy at UMMC to Identify
Risk Factors for Neurotoxicity |
Open |
| 2476GCCC |
2476GCCC: Investigating the Feasibility of Truebeam Hypersight Cone-Beam CT System
for Radiotherapy Simulation and Planning |
Open |
| 2477GCCC |
A Phase 3 Open-Label, Randomized, Active-Controlled, Multicenter Trial to Evaluate
the Efficacy and Safety of Orally Administered BAY 2927088 Compared with Standard
of Care as a First-Line Therapy in Patients with Locally Advanced or Metastatic Non-Small
Cell Lung Cancer (NSCLC) with HER2-Activating Mutations |
Open |
| 2480GCCC |
NXDC-OVA-302 - A Phase 3 Multicenter Study of Gleolan® (Aminolevulinic Acid Hydrochloride)
to Enhance Visualization of Tumor in Patients with Suspected Newly Diagnosed or Recurrent
Epithelial Ovarian Cancer |
Open |
| 2481GCCC |
2481GCCC: Optimizing Hybrid Applicator Brachytherapy for the treatment of Advanced
Cervical Cancer with Use of Machine Learning |
Open |
| 2483GCCC |
2483GCCC: The Utilization And Effectiveness Of Neurohormonal Inhibitors In Preventing
Anthracycline-Induced Cardiotoxicity In Breast Cancer Patients Using Real-World Data. |
Open |
| 2487GCCC |
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene
Autoleucel Versus Standard of Care Therapy in Participants with Relapsed/Refractory
Multiple Myeloma |
Open |
| 2488GCCC |
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic
Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary
Myelofibrosis |
Open |
| 2491GCCC |
2491GCCC: A Pre-Post Interventional Study Evaluating Gardasil Nine-valent Human Papilloma
Virus (HPV) Vaccine Humoral and Cellular Immune Responses in Sexual and Gender Minorities
with or without HIV |
Open |
| 2492GCCC |
2492GCCC: Longitudinal assessment of the role of interoception in chemotherapy-induced
peripheral neurotoxicity (CIPN) along the cancer chemotherapy continuum |
Open |
| 2494GCCC |
Practical clinical interventions to help improve cancer care for patients who live
in food priority areas (FPAs) or food deserts. |
Open |
| 2497GCCC |
A Phase 1 Single-Arm Single-Institution Study Evaluating Neoadjuvant Chemoimmunotherapy
with Immuno-sensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
(NeoRADjuvant Trial) |
Open |
| 2501GCCC |
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101)
or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive,
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
Open |
| 2505GCCC |
2505GCCC: Studying mind-body relations in chemotherapy-induced peripheral neurotoxicity
(CIPN) using functional near infrared spectroscopy (fNIRS) |
Open |
| 25109GCCC |
Predictive Potential of Radiomics for Treatment Response to Neoadjuvant Radiation
in Soft tissue Sarcomas
|
Open |
| 2510GCCC |
Transcriptomic Analysis of Prostate Cancer Specimens |
Open |
| 25115GCCC |
Outcomes after failure of first line hypomethylating agent and venetoclax for acute
myeloid leukemia |
Open |
| 2511GCCC |
A Prospective, Multicenter, Open-Label, Randomized, Actively Controlled, Parallel-Group
Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus
Investigator's Choice of Treatment in Patients with Previously Treated, Unresectable
or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301) |
Open |
| 2513GCCC |
A Phase I/II Study of Subcutaneous Daratumumab Administration in the Anterior Upper
Thigh Vs Abdomen in Patients with Plasma Cell Disorders |
Open |
| 2515GCCC |
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of
ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected
Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma
Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic
Large-cell Lymphoma |
Open |
| 2523GCCC |
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants
with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01) |
Open |
| 2524GCCC |
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib
Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell
Lymphoma |
Open |
| 2525GCCC |
A Prospective Study to Evaluate the Disease Status in Patients with Sickle Cell Disease:
A Globin Regional Data and Discovery (GRNDaD) Network |
Open |
| 2528GCCC |
A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary
Efficacy of ACE-232 in Patients with Metastatic Castration-Resistant Prostate Cancer
(CRPC) |
Open |
| 2534GCCC |
Predictors of recurrence of advanced temporal bone malignancies following temporal
bone resection |
Open |
| 2537GCCC |
A Pivotal Study of Voro Urologic Scaffold for the Prophylactic Treatment of Post Prostatectomy
Stress Urinary Incontinence (ARID II) |
Open |
| 2540GCCC |
Metabotyping of a functional food, broccoli microgreen, in obese breast cancer survivors |
Open |
| 2543GCCC |
University of Maryland Greenebaum Comprehensive Cancer Center Lung Cancer Prevention
Program |
Open |
| 2548GCCC |
TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of
Patients with Head & Neck Squamous Cell Carcinoma (HNSCC) |
Open |
| 2551GCC |
Assessing the long-term impact of prostate radiation therapy for men with low, intermediate-
and high-risk prostate cancer
|
Open |
| 2553GCCC |
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety
of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator's Choice
in Participants with Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4) |
Open |
| 2555GCCC |
A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study
to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid
(Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary
Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation
Antigen×CD3 - Directed Bispecific Antibody Therapy. |
Open |
| 2561GCCC |
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20
Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Open |
| 2563GCC |
Phase III Randomized Trial of Conventionally Fractionated vs. Hypo fractionated
COM-prehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Protons
Therapy (COMPRO) PCG BRE009-23 |
Open |
| 2573GCCC |
Pathologic Response and Post-Surgical Outcomes in a Pan-Tumor Neoadjuvant Immunotherapy
Treated Cohort |
Open |
| 2575GCCC |
A Phase 1b/2 Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20
Bispecific CAR-T Cell Therapy in Adult Participants with B-cell Non-Hodgkin Lymphoma |
Not Open |
| 2577GCCC |
Evaluating if increased vascularity on Brain Magnetic Resonance Imaging correlates
with poor prognosis in Glioblastoma patients |
Open |
| 2579GCCC |
Palliative Care Experiences Among Older Adult African Americans Living with Cancer
|
Open |
| 2582GCCC |
Pulmonary Complications of Acute Myeloid Leukemia |
Open |
| 2588GCC |
Dosimetric Impact of Delivering Deep Inspiration Breath Hold (DIBH) Breast Radiotherapy
Plans on Free Breathing (FB) Anatomy |
Open |
| A011202 |
A RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF AXILLARY LYMPH
NODE DISSECTION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH
NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY |
Open (affiliates only) |
| A011502 |
Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative
Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy |
Open (affiliates only) |
| A011801 |
Alliance A011801, The CompassHER2 trials (Comprehensive use of Pathologic Response
Assessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual
Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared
with T-DM1 and tucatinib (NCT #0445-7596) |
Open (affiliates only) |
| A012303 |
ShortStop-HER2: Shortened duration of adjuvant therapy in patients with early-stage
HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade.
|
Open |
| A021806 |
A021806: A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE
PANCREATIC CANCER |
Open |
| A031803 |
A031803: Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in
the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer |
Open (affiliates only) |
| A032103 |
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant
ThErapy in URothelial CaNcer |
Open |
| A081801 |
Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO |
Open |
| A092205 |
Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent
or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease
|
Open |
| A151804 |
A151804: Establishment of a National Biorepository to Advance Studies of Immune-Related
Adverse Events |
Open (affiliates only) |
| A172401 |
Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits
and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated
in Community Oncology Clinics / WF2304-A172401 |
Open |
| A212102 |
A212102:Blinded Reference Set for Multicancer Early Detection Blood Tests |
Open |
| A222004 |
A222004:A RANDOMIZED PHASE III TRIAL OF OLANZAPINE VERSUS MEGESTROL ACETATE FOR CANCER-ASSOCIATED
ANOREXIA |
Open |
| AALL1732 |
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed
High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype
Acute Leukemia, and Disseminated B-LLy |
Open |
| AAML1831 |
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy
Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3
Inhibitor Gilteritinib for Patients with FLT3 Mutations
|
Open |
| ALTE21C1 |
Assessment of Clonal Hematopoiesis and its Relationship to Cardiovascular Disease
in Hodgkin Lymphoma Survivors |
Open |
| AM0010-301 |
A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX
Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has
Progressed During or Following a First- Line Gemcitabine Containing Regimen |
Open |
| ANBL1531 |
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to
Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) |
Open |
| ANBL2131 |
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children
with Newly Diagnosed High-Risk Neuroblastoma |
Open |
| AOST2032 |
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib
in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma |
Open |
| AREN2231 |
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) |
Open |
| ARST2032 |
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk
Fusion Negative Rhabdomyosarcoma |
Open |
| CCTGMA39 |
TAILOR RT: TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk
Node Positive and T3N0 Breast Cancer |
Open |
| EA2234 |
A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment
vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II |
Open |
| EA3191 |
EA3191 A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection
of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
|
Open |
| EA3231 |
A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory
Differentiated Thyroid Cancer with BRAF V600Em |
Open |
| EA5221 |
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the
Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study |
Open |
| EA9213 |
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory
Minimal Residual Disease (MRD) in T cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)
|
Open |
| EAY191-E5 |
EAY191-E5: ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib)
with or without Panitumumab in Advanced Solid Tumors |
Open |
| EAY191-N4 |
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With
Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers |
Open |
| EAY191-N5 |
A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination With
Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other
Solid Tumors |
Open |
| GO42784 |
GO42784: A PHASE III, RANDOMIZED,OPEN-LABEL, MULTICENTER STUDY EVALUATING THE
EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT
ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY
BREAST CANCER |
Open (affiliates only) |
| HP-00081580HUD |
Deep Regional Hyperthermia Combined with Radiotherapy for the
Treatment of Locally Advanced Tumors in the Pelvis and Abdomen |
Open |
| HP-00095525 |
PATH/HITCH: Prospective Analysis of Transgender Individuals At-Risk and Living with
HIV to understand the impact of Integrating HIV Treatment and Prevention into Transgender
Care Utilizing Hormone Therapy (HP-00095525) |
Open |
| MTG-015 |
MTG-015: Tissue and Bodily Fluids: Discovery and evaluation of biomarkers for the
diagnosis and treatment of disease |
Open (affiliates only) |
| NRG-BN011 |
A Phase III Trial of Lomustine-Temozolomide Combination
Therapy Versus Standard Temozolomide in Patients with Methylated MGMT
Promoter Glioblastoma |
Open |
| NRG-BN013 |
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated
SRS (FSRS) for Intact Brain Metastases |
Open |
| NRG-CC009 |
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant
Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell
Lung Cancer
|
Open |
| NRG-CC010 |
A Phase III Trial of the Impact of Sentinel Lymph Node Mapping on Patient Reported
Lower Extremity Limb Dysfunction in Endometrial Cancer |
Open |
| NRG-CC014 |
Radiation Therapy for High-Risk Asymptomatic Bone
Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical
Trial (PREEMPT) |
Open |
| NRG-CC015 |
HARNESSING E-MINDFULNESS APPROACHES FOR LIVING AFTER BREAST CANCER-HEAL-ABC |
Open |
| NRG-GI003 |
A PHASE III RANDOMIZED TRIAL OF PROTONS VERSUS PHOTONS
FOR HEPATOCELLULAR CARCINOMA |
Open (affiliates only) |
| NRG-GI008 |
NRG-GI008:Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
|
Open |
| NSABP-B-64 |
NSABP B-64: Exact Sciences Corporation / EXActDNA-003: Breast Cancer Clinical Validation
Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant
Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
(NSABP B-64) |
Open (affiliates only) |
| NSABP-C-14 |
NSABP-C-14:CORRECT- MRD II: Second Colorectal cancer clinical validation study to
predict Recurrence using a Circulating Tumor DNA assay to detect Minimal Residual
Disease |
Open |
| S1501 |
Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive
Breast Cancer |
Open |
| S2114 |
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment
for Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma |
Open |
| S2212 |
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in
Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study |
Open |